Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management

Asia Pac J Ophthalmol (Phila). 2024 Mar-Apr;13(2):100058. doi: 10.1016/j.apjo.2024.100058. Epub 2024 Apr 12.

Abstract

Retinoblastoma, the primary ocular malignancy in pediatric patients, poses a substantial threat to mortality without prompt and effective management. The prognosis for survival and preservation of visual acuity hinges upon the disease severity at the time of initial diagnosis. Notably, retinoblastoma has played a crucial role in unraveling the genetic foundations of oncogenesis. The process of tumorigenesis commonly begins with the occurrence of biallelic mutation in the RB1 tumor suppressor gene, which is then followed by a cascade of genetic and epigenetic alterations that correspond to the clinical stage and pathological features of the tumor. The RB1 gene, recognized as a tumor suppressor, encodes the retinoblastoma protein, which plays a vital role in governing cellular replication through interactions with E2F transcription factors and chromatin remodeling proteins. The diagnosis and treatment of retinoblastoma necessitate consideration of numerous factors, including disease staging, germline mutation status, family psychosocial factors, and the resources available within the institution. This review has systematically compiled and categorized the latest developments in the diagnosis and treatment of retinoblastoma which enhanced the quality of care for this pediatric malignancy.

Keywords: Diagnosis; Genetic and epigenetic alterations; Pathogenesis; Retinoblastoma.

Publication types

  • Review

MeSH terms

  • Disease Management
  • Humans
  • Retinal Neoplasms* / diagnosis
  • Retinal Neoplasms* / genetics
  • Retinal Neoplasms* / therapy
  • Retinoblastoma* / diagnosis
  • Retinoblastoma* / genetics
  • Retinoblastoma* / therapy